OBJECTIVE: Both the state of pregnancy as well as disruption of vaginal flora and immune mediators may increase the risk of human immunodeficiency virus-1 acquisition. The objective of this study was to define immune changes in lower genital and systemic immunity associated with normal pregnancy. STUDY DESIGN: This prospective cohort enrolled low-risk pregnant and nonpregnant women ages 18-35 years. Pregnant women at <14 weeks and nonpregnant women in follicular phase of the menstrual cycle were included. Cervical and vaginal fluid was collected. Concentrations of immune mediators were measured using enzyme-linked immunosorbent assay-based methods or multiplex immunoassay. Samples were inoculated onto various culture media allowing for growth of Lactobacillus species, Gardnerella vaginalis, Escherichia coli, Enterococcus species, anaerobic gram-negative rods, Candida, Staphylococcus aureus, Ureaplasma species, and Mycoplasma hominis. Concentrations of immune mediators and vaginal colonization frequencies were compared between the pregnant and nonpregnant groups. RESULTS: Genital tract concentration of interleukin-1β was higher during pregnancy compared to nonpregnant participants. Serum C-reactive protein concentrations were higher in all trimesters of pregnancy. Concentrations of secretory leukocyte protease inhibitor did not differ between groups. Lactobacillus was more commonly isolated from vaginal cultures of nonpregnant participants (100% vs 70.2%, P = .02). Identification of Candida, G vaginalis, M hominis, and S aureus was common and not different between groups. Ureaplasma species was isolated from >60% pregnant participants. CONCLUSION: The proinflammatory cytokine, interleukin-1β, as well as the systemic marker of inflammation, C-reactive protein, are increased during pregnancy. The impact of these proinflammatory changes during pregnancy deserves further study.
OBJECTIVE: Both the state of pregnancy as well as disruption of vaginal flora and immune mediators may increase the risk of human immunodeficiency virus-1 acquisition. The objective of this study was to define immune changes in lower genital and systemic immunity associated with normal pregnancy. STUDY DESIGN: This prospective cohort enrolled low-risk pregnant and nonpregnant women ages 18-35 years. Pregnant women at <14 weeks and nonpregnant women in follicular phase of the menstrual cycle were included. Cervical and vaginal fluid was collected. Concentrations of immune mediators were measured using enzyme-linked immunosorbent assay-based methods or multiplex immunoassay. Samples were inoculated onto various culture media allowing for growth of Lactobacillus species, Gardnerella vaginalis, Escherichia coli, Enterococcus species, anaerobic gram-negative rods, Candida, Staphylococcus aureus, Ureaplasma species, and Mycoplasma hominis. Concentrations of immune mediators and vaginal colonization frequencies were compared between the pregnant and nonpregnant groups. RESULTS: Genital tract concentration of interleukin-1β was higher during pregnancy compared to nonpregnant participants. Serum C-reactive protein concentrations were higher in all trimesters of pregnancy. Concentrations of secretory leukocyte protease inhibitor did not differ between groups. Lactobacillus was more commonly isolated from vaginal cultures of nonpregnant participants (100% vs 70.2%, P = .02). Identification of Candida, G vaginalis, M hominis, and S aureus was common and not different between groups. Ureaplasma species was isolated from >60% pregnant participants. CONCLUSION: The proinflammatory cytokine, interleukin-1β, as well as the systemic marker of inflammation, C-reactive protein, are increased during pregnancy. The impact of these proinflammatory changes during pregnancy deserves further study.
Authors: Fausto Gondo; Márcia G da Silva; Jossimara Polettini; Andréa da R Tristao; José C Peracoli; Steven S Witkin; Marilza V C Rudge Journal: Gynecol Obstet Invest Date: 2010-12-14 Impact factor: 2.031
Authors: Brenna L Anderson; Susan Cu-Uvin; Christina A Raker; Christine Fitzsimmons; Sharon L Hillier Journal: Acta Obstet Gynecol Scand Date: 2011-03-14 Impact factor: 3.636
Authors: Rafli van de Laar; David P van der Ham; S Guid Oei; Christine Willekes; Carl P Weiner; Ben W J Mol Journal: Eur J Obstet Gynecol Reprod Biol Date: 2009-10-12 Impact factor: 2.435
Authors: Sarah J Stock; Leanne Duthie; Tina Tremaine; Andrew A Calder; Rodney W Kelly; Simon C Riley Journal: Reprod Sci Date: 2009-09-01 Impact factor: 3.060
Authors: Jan Walter; Linda Fraga; Melanie J Orin; William D Decker; Theresa Gipps; Alice Stek; Grace M Aldrovandi Journal: BMC Infect Dis Date: 2011-09-30 Impact factor: 3.090
Authors: Brenna L Hughes; Riana Dutt; Christina Raker; Melody Barthelemy; Richard M Rossoll; Bharat Ramratnam; Charles R Wira; Susan Cu-Uvin Journal: Am J Obstet Gynecol Date: 2016-07-05 Impact factor: 8.661
Authors: Pao-Chu Hsu; Robert H Yolken; Teodor T Postolache; Theresa M Beckie; Cindy L Munro; Maureen W Groer Journal: Psychosom Med Date: 2016-10 Impact factor: 4.312
Authors: Emma L Sweeney; Suhas G Kallapur; Tate Gisslen; Donna S Lambers; Claire A Chougnet; Sally-Anne Stephenson; Alan H Jobe; Christine L Knox Journal: J Infect Dis Date: 2015-12-15 Impact factor: 5.226
Authors: Raju Gautam; Hanneke Borgdorff; Vicky Jespers; Suzanna C Francis; Rita Verhelst; Mary Mwaura; Sinead Delany-Moretlwe; Gilles Ndayisaba; Jordan K Kyongo; Liselotte Hardy; Joris Menten; Tania Crucitti; Evgeni Tsivtsivadze; Frank Schuren; Janneke H H M van de Wijgert Journal: BMC Infect Dis Date: 2015-02-21 Impact factor: 3.090
Authors: Elizabeth Ann L Enninga; Wendy K Nevala; Douglas J Creedon; Svetomir N Markovic; Shernan G Holtan Journal: Am J Reprod Immunol Date: 2014-08-04 Impact factor: 3.886